Cook enters European coronary stent market with CoCr stent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Global Therapeutics, the cardiology unit of Cook Medical, has received CE Mark approval for its new cobalt chromium bare metal coronary stent (BMS), the GTX coronary stent system, which will be available immediately in the European Union and the United Kingdom.

“Not only do our BMS eliminate the concerns associated with potential delayed reactions from DES in certain coronary patients, our bare metal cobalt chromium stent has advanced features designed to improve clinical performance of BMS in coronary arteries. The GTX stent has been engineered specifically to eliminate the technical challenges, such as recoil, stent balloon retention and stent spring-back, that have been associated with earlier cobalt chromium stent designs currently on the market,” said Joe Horn, president of Global Therapeutics.

The Broomfield, Colo.-based company also is developing DES technology using the GTX platform and an improved application of antisense gene therapy—developed by its partner, AVI BioPharma of Corvallis, Ore.—to inhibit the proliferation of a gene known to induce the restenosis process, Horn said.